Search

Your search keyword '"Dehais, C."' showing total 184 results
Start Over Author "Dehais, C."
184 results on '"Dehais, C."'

1. Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

Author

Thomas-Joulié, A., Tran, S., El Houari, L., Seyve, A., Bielle, F., Birzu, C., Lozano-Sanchez, F., Mokhtari, K., Giry, M., Marie, Y., Laigle-Donadey, F., Dehais, C., Houillier, C., Psimaras, D., Alentorn, A., Laurenge, A., Touat, M., Sanson, M., Hoang-Xuan, K., Kas, A., Rozenblum, L., Habert, M.-O., Nichelli, L., Leclercq, D., Galanaud, D., Jacob, J., Karachi, C., Capelle, L., Carpentier, A., Mathon, B., Belin, L., and Idbaih, A.

Published
2024
Full Text
View/download PDF

2. Human pegivirus identified in severe myelitis and optic neuritis in immunocompromised patients: A pathogenic role for a forgotten virus?

Author

Valyraki, N., primary, Maillart, E., additional, Pourcher, V., additional, Shor, N., additional, Tran, S., additional, Boudot de la Motte, M., additional, Houillier, C., additional, Domont, F., additional, Morvan, E., additional, Touat, M., additional, Del Mar Amador, M., additional, Aboab, J., additional, Mathon, B., additional, Hesters, A., additional, Vignal-Clermont, C., additional, Dehais, C., additional, Bonnin, S., additional, Lafitte, F., additional, Villain, N., additional, Varnous, S., additional, Gout, O., additional, Eloit, M., additional, Rodriguez, C., additional, and Deschamps, R., additional

Published
2022
Full Text
View/download PDF

3. OS07.1.A A threshold of mitotic activity and post-surgery residual volume are independant prognostic factors in astrocytoma IDH-mutant

Author

Tran, S, primary, Thomas, A, additional, Touat, M, additional, Karachi, C, additional, Lozano, F, additional, Mokhtari, K, additional, Dehais, C, additional, Feuvret, L, additional, Carpentier, C, additional, Giry, M, additional, Doukani, H, additional, Lerond, J, additional, Marie, Y, additional, Sanson, M, additional, Idbaih, A, additional, Carpentier, A, additional, Hoang-Xuan, K, additional, Capelle, L, additional, and Bielle, F, additional

Published
2022
Full Text
View/download PDF

5. The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches

Author

Billard, P., primary, Guerriau, C., additional, Carpentier, C., additional, Juillard, F., additional, Grandin, N., additional, Lomonte, P., additional, Kantapareddy, P., additional, Dufay, N., additional, Barritault, M., additional, Rimokh, R., additional, Verrelle, P., additional, Maucort-Boulch, D., additional, Figarella-Branger, D., additional, Ducray, F., additional, Dehais, C., additional, Charbonneau, M., additional, Meyronet, D., additional, and Poncet, D.A., additional

Published
2021
Full Text
View/download PDF

6. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states

Author

Blay, J-Y, Casali, P, Bouvier, C, Dehais, C, Galloway, I, Gietema, J, Halámková, J, Hindi, N, Idbaih, A, Kinloch, E, Klümpen, H-J, Kolarova, T, Kopeckova, K, Lovey, J, Magalhaes, M, Oselin, K, Piperno-Neumann, S, Ravnsbaek, A, Rogasik, M, Safwat, A, Scheipl, S, Seckl, M, Taylor, J, Temnyk, M, Trama, A, Urbonas, M, Wartenberg, M, Weinman, A, EURACAN Network, Oncology, CCA - Cancer Treatment and Quality of Life, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], University of Milan, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Royal Free Hospital [London, UK], Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Masaryk Memorial Cancer Institute (RECAMO), Hospital Universitario Virgen del Rocío [Sevilla], University of Amsterdam [Amsterdam] (UvA), University Hospital Motol [Prague], National Institute of Oncology [Budapest, Hungary], Centro Hospitalar do Porto, North Estonia Medical Center, Institut Curie [Paris], Aarhus University Hospital, Karl-Franzens-Universität [Graz, Autriche], Charing Cross Hospital & Imperial College, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Kaunas University of Technology (KTU), EURORDIS-Rare Diseases Europe (Bureau de Paris), EURORDIS - Plateforme Maladies Rares [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and University of Graz

Subjects
Cancer Research, medicine.medical_specialty, Statement (logic), MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, News, GUIDELINES, DIAGNOSIS, 03 medical and health sciences, 0302 clinical medicine, EURACAN Network, Health care, medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, business.industry, Member states, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Family medicine, SURVIVAL, Position paper, SARCOMA PATIENTS, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, BURDEN
Abstract

International audience

Published
2021

7. OS02.6.A The TeloDIAG: How telomeric parameters can help in glioma rapid diagnosis and liquid biopsies approaches

Author

Billard, P, primary, Guerriau, C, additional, Carpentier, C, additional, Juillard, F, additional, Grandin, N, additional, Lomonte, P, additional, Kantapareddy, P, additional, Barritault, M, additional, Rimokh, R, additional, Verrelle, P, additional, Maucort-Boulch, D, additional, Figarella-Branger, D, additional, Ducray, F, additional, Dehais, C, additional, Charbonneau, M, additional, Meyronet, D, additional, and Poncet, D A, additional

Published
2021
Full Text
View/download PDF

8. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)

Author

Ducray, F, primary, Sanson, M, additional, Chinot, O, additional, Fontanilles, M, additional, Rivoirard, R, additional, Thomas-Maisonneuve, L, additional, Cartalat, S, additional, Tabouret, E, additional, Bonneville-Levard, A, additional, Darlix, A, additional, Ameli, R, additional, Meyronet, D, additional, Gueyffier, F, additional, Remontet, L, additional, Maucort-Boulch, D, additional, Dehais, C, additional, and Honnorat, J, additional

Published
2021
Full Text
View/download PDF

9. Human pegivirus identified in severe myelitis and optic neuritis in immunocompromised patients: A pathogenic role for a forgotten virus?

Author

Valyraki, N., Maillart, E., Pourcher, V., Shor, N., Tran, S., Boudot de la Motte, M., Houillier, C., Domont, F., Morvan, E., Touat, M., Del Mar Amador, M., Aboab, J., Mathon, B., Hesters, A., Vignal-Clermont, C., Dehais, C., Bonnin, S., Lafitte, F., Villain, N., Varnous, S., Gout, O., Eloit, M., Rodriguez, C., and Deschamps, R.

Abstract

The role of Human pegivirus (HPgV) in patients with encephalitis has been recently questioned. We present cases of 4 patients with similar clinical, biological, and radiological characteristics, including a past history of transplantation with long-term immunosuppression and a progressive course of severe and predominantly myelitis, associated in 3 cases with optic neuropathy causing blindness. Extensive workup was negative but analysis of the CSF by use of pan-microorganism DNA- and RNA-based shotgun metagenomics was positive for HPgV. This case series further supports the hypothesis of HPgV CNS infection and highlights the utility of metagenomic next-generation sequencing of CSF in immunocompromised patients.

Published
2023
Full Text
View/download PDF

14. Rare Primary Central Nervous System Tumors in Adults: An Overview

Author

Franceschi, C. (Claudio), Frappaz, D., Ruda, R, Hau, P. (Peter), Preusser, M. (Matthias), Houillier, C., Lombardi, G. (Grazia), Asioli, S., Dehais, C., Bielle, F., Di Nunno, V., Bent, M.J. (Martin) van den, Brandes, A. (Alba), Idbaih, A. (Ahmed), Franceschi, C. (Claudio), Frappaz, D., Ruda, R, Hau, P. (Peter), Preusser, M. (Matthias), Houillier, C., Lombardi, G. (Grazia), Asioli, S., Dehais, C., Bielle, F., Di Nunno, V., Bent, M.J. (Martin) van den, Brandes, A. (Alba), and Idbaih, A. (Ahmed)

Abstract

Overall, tumors of primary central nervous system (CNS) are quite common in adults with an incidence rate close to 30 new cases/100,000 inhabitants per year. Significant clinical and biological advances have been accomplished in the most common adult primary CNS tumors (i.e., diffuse gliomas). However, most CNS tumor subtypes are rare with an incidence rate below the threshold defining rare disease of 6.0 new cases/100,000 inhabitants per year. Close to 150 entities of primary CNS tumors have now been identified by the novel integrated histomolecular classification published by the World Health Organization (WHO) and its updates by the c-IMPACT NOW consortium (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). While these entities can be better classified into smaller groups either by their histomolecular features and/or by their location, assessing their treatment by clinical trials and improving the survival of patients remain challenging. Despite these tumors are rare, research, and advances remain slower compared to diffuse gliomas for instance. In some cases (i.e., ependymoma, medulloblastoma) the understanding is high because single or few driver mutations have been defined. The European Union has launched European Reference Networks (ERNs) dedicated to support advances on the clinical side of rare diseases including rare cancers. The ERN for rare solid adult tumors is termed EURACAN. Within EURACAN, Domain 10 brings together the European patient advocacy groups (ePAGs) and physicians dedicated to improving outcomes in rare primary CNS tumors and also aims at supporting research, care and teaching in the field. In this review, we discuss the relevant biological and clinical characteristics, clinical management of patients, and research directions for the following types of rare primary CNS tumors: medulloblastoma, pineal region tumors, glioneuronal and rare glial tumors, ependymal tumors, grade III meningioma and mesenchymal tu

Published
2020
Full Text
View/download PDF

15. Rare Primary Central Nervous System Tumors in Adults: An Overview

Author

Franceschi, E, Frappaz, D, Ruda, R, Hau, P, Preusser, M, Houillier, C, Lombardi, G, Asioli, S, Dehais, C, Bielle, F, Di Nunno, V, van den Bent, Martin, Brandes, AA, Idbaih, A, Franceschi, E, Frappaz, D, Ruda, R, Hau, P, Preusser, M, Houillier, C, Lombardi, G, Asioli, S, Dehais, C, Bielle, F, Di Nunno, V, van den Bent, Martin, Brandes, AA, and Idbaih, A

Published
2020

16. Ki-67 and MCM6 labelling index are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q codeleted: a multicenter study from the French POLA Network

Author

Pouget, Celso, Hergalant, Sébastien, Lardenois, Emilie, Battaglia-Hsu, Shyue-Fang, Houlgatte, Rémi, Carpentier, C, Dehais, C., Rech, Fabien, Taillandier, Luc, Colin, Carole, Figarella‑Branger, Dominique, Gauchotte, Guillaume, Service de Pathologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de neurologie [CHRU Nancy], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[INFO.INFO-DB]Computer Science [cs]/Databases [cs.DB], [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], [SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.BBM.MN]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular Networks [q-bio.MN], [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], [INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM], [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]
Abstract

International audience; Background & Objectives: Anaplastic oligodendroglioma (AO), IDH-mutant and 1p/19q codeleted (IDHmut+/1p19qcodel) are high grade gliomas. Only few prognostic markers were studied in this specific histomolecular subgroup. The primary aim of this study was to evaluate and compare the prognostic value of two proliferation markers, MCM6 and Ki-67, in a French multicenter series of IDHmut+/1p19qcodel AO (POLA network), using immunohistochemistry. Further transcriptomic approaches were implemented to uncover the molecular pathways associated with the overexpression of these markers.Methods: Two hundred and thirty-one IDHmut+/1p19qcodel AO cases were included from the French national POLA network. MCM6 and Ki-67 labelling index (LI) were evaluated using computer color image analyser. Transcriptomic data were analysed in a subset of 68 microarray samples from the French POLA Network.Results: High MCM6 (≥ 50%) and Ki-67 (≥ 15%) LI correlated with shorter overall survival (P=0.013 and P=0.004, respectively). A high proliferation index, defined by MCM6 ≥ 50% and/or Ki-67 ≥ 15%, was independently correlated to a shorter survival (P=0.027; multivariate Cox model including age, mitotic index, MCM6 and Ki-67). Transcriptomic analyses revealed that while the high mRNA level of both MCM6 and Ki-67 were positively associated with clusters enriched in gene functions like cell cycle progression, DNA replication, mitosis, pro-neural phenotype as well as neurogenesis, they were negatively associated with clusters of other functions like microglial cell activation, immune response, positive regulation of myelination, oligodendrocyte development, beta-amyloid binding, and postsynaptic specialization.Conclusion: In conclusion, both MCM6 and Ki-67 LI were correlated to overall survival. Because multivariate analyses showed that overexpression of MCM6 and/or Ki-67 was independently correlated to shorter survival, these two easy-to-use and costless markers could be used in association in daily practice in order to predict clinical outcome. Transcriptomics showed that IDHmut+/1p19qcodel AO are highly proliferative tumours with upregulated pro-neural phenotype associated genes, and downregulated immune response, glial differentiation, and myelin-related function.

Published
2019

17. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study

Author

Montégut, C., primary, Guillamo, J.-S., additional, Ducray, F., additional, Dehais, C., additional, Chinot, O., additional, Cohen-Jonathan Moyal, E.L., additional, Le Rhun, E., additional, Loiseau, H., additional, Appay, R., additional, Figarella-Branger, D., additional, Delattre, J.-Y., additional, and Tabouret, E., additional

Published
2019
Full Text
View/download PDF

19. OS9.2 Radiomics analysis of lower-grade gliomas, a POLA Network study

Author

Younan, N, primary, Douzane, H, additional, Duran-Pena, A, additional, Nichelli, L, additional, Garcilazo, Y, additional, Dehais, C, additional, Ducray, F, additional, Carpentier, C, additional, Mokhtari, K, additional, Figarella-Branger, D, additional, Delattre, J, additional, Idbaih, A, additional, and Alentorn, A, additional

Published
2019
Full Text
View/download PDF

23. Contrôle qualité de la radiothérapie dans le cadre de l’essai randomisé Polca : revue cas par cas des dossiers techniques par le Groupe de radiothérapie de l’Association des neuro-oncologues d’expression-française (Granocef)

Author

Feuvret, L., primary, Douzane, H., additional, Jenny, C., additional, D’hombres, A., additional, Padovani, L., additional, Aumont, M., additional, Hanzen, C., additional, Noel, G., additional, Jacob, J., additional, Riet, F., additional, Canova, C.H., additional, Dehais, C., additional, and Dhermain, F., additional

Published
2018
Full Text
View/download PDF

24. Association de radiothérapie et de chimiothérapie-thérapeutiques ciblées dans les glioblastomes

Author

Laigle-Donadey F, Marc Sanson, Dehais C, and Jean-Jacques Mazeron

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Temozolomide, Bevacizumab, Performance status, business.industry, medicine.medical_treatment, Cancer, Hematology, General Medicine, medicine.disease, Surgery, Targeted therapy, Irinotecan, Radiation therapy, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, medicine.drug
Abstract

Despite recent and significant progress, the prognosis of glioblastoma remains extremely poor. Concomitant chemoradiotherapy with temozolomide is now the standard of care for newly diagnosed glioblastoma. This treatment is well-tolerated and results in improvement of overall survival and dramatic increase of long term survivor rate, especially in good performance status patients. Besides, this benefit is particularly marked in patients with MGMT (methylguanine methyltransferase) methylated tumor, suggesting a growing place of molecular markers in pattern of care of such patients. At recurrence, the combination of bevacizumab (anti-VEGF) with irinotecan has shown surprising high response rates in a phase II trial for recurrent malignant gliomas. Many other targeted therapies are currently under investigation, alone or in association, at recurrence or up-front and during radiotherapy. For this reason, in the future a more precise understanding of gliomagenesis is needed for a better molecular stratification of patients.

Published
2009

30. Ouverture de la barrière hémato-encéphalique par un dispositif ultrasonore implantable : résultats pré-cliniques sur primates et résultats préliminaires de l’essai clinique SonoCloud de phase I/Iia

Author

Carpentier, A., primary, Canney, M., additional, Horodyckid, C., additional, Leclercq, D., additional, Vignot, A., additional, Beccaria, K., additional, Boisgard, R., additional, Goldwirt, L., additional, Reina, V., additional, Lafon, C., additional, Chapelon, J., additional, Capelle, L., additional, Dehais, C., additional, Cornu, P., additional, Delattre, J., additional, and Idbaih, A., additional

Published
2014
Full Text
View/download PDF

32. L'homogénéisation biotique des communautés

Author

Devictor, Vincent, Mouquet, N., Dehais, C., Université Montpellier 2 - Sciences et Techniques (UM2), Hydrobiologie (UR HYAX), and Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF)

Subjects
[SDE]Environmental Sciences
Abstract

National audience; L'homogénéisation biotique des communautés.

Published
2008

41. Supratentorial low-grade gliomas in older patients

Author

Kaloshi, G., primary, Psimaras, D., additional, Mokhtari, K., additional, Dehais, C., additional, Houillier, C., additional, Marie, Y., additional, Laigle-Donadey, F., additional, Taillibert, S., additional, Guillevin, R., additional, Martin-Duverneuil, N., additional, Sanson, M., additional, Hoang-Xuan, K., additional, and Delattre, J. -Y., additional

Published
2009
Full Text
View/download PDF

42. Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas

Author

Houillier, C., primary, Mokhtari, K., additional, Carpentier, C., additional, Criniere, E., additional, Marie, Y., additional, Rousseau, A., additional, Kaloshi, G., additional, Dehais, C., additional, Laffaire, J., additional, Laigle-Donadey, F., additional, Hoang-Xuan, K., additional, Sanson, M., additional, and Delattre, J.-Y., additional

Published
2009
Full Text
View/download PDF

43. Bevacizumab and irinotecan for recurrent oligodendroglial tumors

Author

Taillibert, S., primary, Vincent, L. A., additional, Granger, B., additional, Marie, Y., additional, Carpentier, C., additional, Guillevin, R., additional, Bellanger, A., additional, Mokhtari, K., additional, Rousseau, A., additional, Psimaras, D., additional, Dehais, C., additional, del Rio, M. Sierra, additional, Meng, Y., additional, Laigle-Donadey, F., additional, Hoang-Xuan, K., additional, Sanson, M., additional, and Delattre, J. Y., additional

Published
2009
Full Text
View/download PDF

44. α-Internexin expression identifies 1p19q codeleted gliomas

Author

Ducray, F., primary, Crinière, E., additional, Idbaih, A., additional, Mokhtari, K., additional, Marie, Y., additional, Paris, S., additional, Navarro, S., additional, Laigle-Donadey, F., additional, Dehais, C., additional, Thillet, J., additional, Hoang-Xuan, K., additional, Delattre, J. -Y., additional, and Sanson, M., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results